Status:
NO_LONGER_AVAILABLE
Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
Lead Sponsor:
David Lacomis, MD
Collaborating Sponsors:
Jacobus Pharmaceutical
Conditions:
Lambert-Eaton Myasthenic Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to provide expanded access (compassionate use) of 3,4 diaminopyridine to patients with Lambert-Eaton myasthenic syndrome (LEMS).
Detailed Description
Up to 15 patients over the age of 18 years with a diagnosis of LEMS are eligible to enroll if they are medically stable. They may receive 3,4 diaminopyridine in addition to other treatments and standa...
Eligibility Criteria
Inclusion
- Diagnosis of LEMS
- Over 18 years old
- Medically stable
- If female and premenopausal, have a negative urine pregnancy test prior to starting the 3,4 DAP, and, if premenopausal, be willing to practice an effective form of birth control such as "double-barrier contraception" during the study
Exclusion
- Known sensitivity to 3,4 DAP
- History of past or current seizures
- History of severe asthma
- Believed by the investigator to be unable to comply with the protocol
- Unable to provide informed consent
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00994916
Last Update
July 9 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.